Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:
Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Inclusion Criteria:
Exclusion Criteria:
regulatory-006@catalym.com49 8920006640
Sofia, 1527, Bulgaria
Dresden, 01307, Germany
Meldola, 47014, Italy
Lodz, 93-513, Poland
Lublin, 20-064, Poland
A Coruña, 15006, Spain